25 results on '"Rizzetti MC"'
Search Results
2. Blindness, deafness and polyneuropathy: a case of cobalt neurotoxicity
- Author
-
Rizzetti, Mc, Liberini, P, Agosti, C, Catalani, S, Apostoli, P, Zarattini, G, De Maria, G, and Padovani, A
- Subjects
metal ions intoxication ,metal ions intoxication, polyneuropathy ,polyneuropathy - Published
- 2009
3. Loss of Synaptic D1 Dopamine/N-Methyl-D-aspartate Glutamate Receptor Complexes in L-DOPA-Induced Dyskinesia in the Rat
- Author
-
Fiorentini, Chiara, Rizzetti, Mc, Busi, C, Bontempi, S, Collo, Luigia Rinalda, Spano, Pier Franco, and Missale, Mariacristina
- Subjects
heterodimerization ,parkinson's disease ,dopamine - Published
- 2006
4. Neurotoxicity of cobalt
- Author
-
Catalani, S, primary, Rizzetti, MC, additional, Padovani, A, additional, and Apostoli, P, additional
- Published
- 2011
- Full Text
- View/download PDF
5. Blind and deaf after total hip replacement? – Authors' reply
- Author
-
Rizzetti, MC, primary, Zarattini, G, additional, Pazzaglia, U, additional, and Padovani, A, additional
- Published
- 2009
- Full Text
- View/download PDF
6. Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145
- Author
-
Sigala, S, primary, Tognazzi, N, additional, Rizzetti, MC, additional, Faraoni, I, additional, Missale, C, additional, Bonmassar, E, additional, and Spano, P, additional
- Published
- 2002
- Full Text
- View/download PDF
7. Neurotoxicity of cobalt.
- Author
-
Catalani, S, Rizzetti, MC, Padovani, A, and Apostoli, P
- Subjects
- *
COBALT , *NEUROTOXICOLOGY , *NEUROLOGIC manifestations of general diseases , *TRANSITION metals , *TINNITUS , *VERTIGO , *PHYSIOLOGY , *PATIENTS - Abstract
Cobalt exerts well-known and documented toxic effects on the thyroid, heart and the haematopoietic system, in addition to the occupational lung disease, allergic manifestations and a probably carcinogenic action. Cobalt neurotoxicity is reported in isolated cases, and it has never been systematically treated. Bilateral optic atrophy and retinopathy, bilateral nerve deafness and sensory-motor polyneuropathy have been described long ago as a result of chronic occupational exposure to cobal powder or during long-term treatment of anaemia with cobalt chloride. Recently, some patients with high levels of cobalt released from metal prosthesis have been referred as presenting with tinnitus, deafness, vertigo, visual changes, optic atrophy, tremor and peripheral neuropathy. The aim of this work is to group these cases and to identify a possible mechanism of cobalt neurotoxicity, focusing on hypothetic individual susceptibility such as altered metal-binding proteins, altered transport processes in target cells or polymorphic variation of genetic background. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
8. The role of albumin in human toxicology of cobalt: contribution from a clinical case.
- Author
-
Catalani S, Leone R, Rizzetti MC, Padovani A, and Apostoli P
- Abstract
The distribution and adverse effects, especially to optic and acoustic nerves, of cobalt released from a hip arthroplasty and its association with albumin were studied. The analysis of cobalt was performed in plasma, whole blood, urine, and cerebrospinal fluid by inductively coupled plasma mass spectrometry (ICP-MS). The fraction of albumin binding the metal was determined by colorimetric assay using dithiothreitol (DTT). In all the biological matrices very high levels of cobalt were measured, but contrary to expected, a higher concentration in whole blood than in plasma was observed. The determination of altered albumin confirmed this hypothesis. This evidence might indicate an alteration in the binding of cobalt to albumin and a consequent increase in the concentration of the diffusible (free) fraction of the metal. This appears an interesting starting point for further investigations for identifying and better understanding cobalt neurotoxicity, apparently not so frequent in occupational medicine and clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
9. Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders.
- Author
-
Pilotto A, Romagnolo A, Scalvini A, Masellis M, Shimo Y, Bonanni L, Camicioli R, Wang LL, Dwivedi AK, Longardner K, Rodriguez-Porcel F, DiFrancesco M, Vizcarra JA, Montanaro E, Maule S, Lupini A, Ojeda-López C, Black SE, Delli Pizzi S, Gee M, Tanaka R, Yamashiro K, Hatano T, Borroni B, Gasparotti R, Rizzetti MC, Hattori N, Lopiano L, Litvan I, Espay AJ, Padovani A, and Merola A
- Subjects
- Aged, Aged, 80 and over, Atrophy pathology, Female, Humans, Hypotension, Orthostatic etiology, Lewy Body Disease complications, Lewy Body Disease diagnostic imaging, Magnetic Resonance Imaging, Male, Middle Aged, Parkinson Disease complications, Parkinson Disease diagnostic imaging, Severity of Illness Index, Temporal Lobe diagnostic imaging, White Matter diagnostic imaging, Hypotension, Orthostatic physiopathology, Lewy Body Disease pathology, Parkinson Disease pathology, Temporal Lobe pathology, White Matter pathology
- Abstract
Objective: To evaluate whether orthostatic hypotension (OH) or supine hypertension (SH) is associated with brain atrophy and white matter hyperintensities (WMH), we analyzed clinical and radiologic data from a large multicenter consortium of patients with Parkinson disease (PD) and dementia with Lewy bodies (DLB)., Methods: Supine and orthostatic blood pressure (BP) and structural MRI data were extracted from patients with PD and DLB evaluated at 8 tertiary-referral centers in the United States, Canada, Italy, and Japan. OH was defined as a systolic/diastolic BP fall ≥20/10 mm Hg within 3 minutes of standing from the supine position (severe ≥30/15 mm Hg) and SH as a BP ≥140/90 mm Hg with normal sitting BP. Diagnosis-, age-, sex-, and disease duration-adjusted differences in global and regional cerebral atrophy and WMH were appraised with validated semiquantitative rating scales., Results: A total of 384 patients (310 with PD, 74 with DLB) met eligibility criteria, of whom 44.3% (n = 170) had OH, including 24.7% (n = 42) with severe OH and 41.7% (n = 71) with SH. OH was associated with global brain atrophy ( p = 0.004) and regional atrophy involving the anterior-temporal ( p = 0.001) and mediotemporal ( p = 0.001) regions, greater in severe vs nonsevere OH ( p = 0.001). The WMH burden was similar in those with and without OH ( p = 0.49). SH was not associated with brain atrophy ( p = 0.59) or WMH ( p = 0.72)., Conclusions: OH, but not SH, was associated with cerebral atrophy in Lewy body disorders, with prominent temporal region involvement. Neither OH nor SH was associated with WMH., (© 2021 American Academy of Neurology.)
- Published
- 2021
- Full Text
- View/download PDF
10. Cerebellar rTMS in PSP: a Double-Blind Sham-Controlled Study Using Mobile Health Technology.
- Author
-
Pilotto A, Rizzetti MC, Lombardi A, Hansen C, Biggi M, Verzeroli G, Martinelli A, Romijnders R, Borroni B, Maetzler W, and Padovani A
- Subjects
- Biomedical Technology, Cerebellum, Double-Blind Method, Humans, Treatment Outcome, Supranuclear Palsy, Progressive therapy, Transcranial Magnetic Stimulation methods
- Abstract
There are no effective treatments in progressive supranuclear palsy (PSP). The aim of this study was to test the efficacy of theta burst repetitive transcranial magnetic stimulation (rTMS) on postural instability in PSP. Twenty PSP patients underwent a session of sham or real cerebellar rTMS in a crossover design. Before and after stimulation, static balance was evaluated with instrumented (lower back accelerometer, Rehagait®, Hasomed, Germany) 30-s trials in semitandem and tandem positions. In tandem and semitandem tasks, active stimulation was associated with increase in time without falls (both p=0.04). In the same tasks, device-extracted parameters revealed significant improvement in area (p=0.007), velocity (p=0.005), acceleration and jerkiness of sway (p=0.008) in real versus sham stimulation. Cerebellar rTMS showed a significant effect on stability in PSP patients, when assessed with mobile digital technology, in a double-blind design. These results should motivate larger and longer trials using non-invasive brain stimulation for PSP patients., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
11. Plasma NfL, clinical subtypes and motor progression in Parkinson's disease.
- Author
-
Pilotto A, Imarisio A, Conforti F, Scalvini A, Masciocchi S, Nocivelli S, Turrone R, Gipponi S, Cottini E, Borroni B, Rizzetti MC, Pizzi M, Bonanni L, Sturchio A, Espay AJ, Zetterberg H, Ashton NJ, Hye A, and Padovani A
- Subjects
- Aged, Aged, 80 and over, Cognitive Dysfunction etiology, Female, Follow-Up Studies, Humans, Hypotension, Orthostatic etiology, Male, Middle Aged, Parkinson Disease complications, Phenotype, REM Sleep Behavior Disorder etiology, Disease Progression, Neurofilament Proteins blood, Parkinson Disease blood, Parkinson Disease classification, Parkinson Disease physiopathology
- Abstract
Introduction: neurofilament light chain (NfL) levels have been proposed as reliable biomarkers of neurodegeneration in Parkinson's disease (PD) but the relationship between plasma NfL, clinical subtypes of PD and motor progression is still debated., Methods: plasma NfL concentration was measured in 45 healthy controls and consecutive 92 PD patients who underwent an extensive motor and non-motor assessment at baseline and after 2 years of follow-up. PD malignant phenotype was defined as the combination of at least two out of cognitive impairment, orthostatic hypotension and REM sleep behavior disorder. PD patients were divided according to the age-adjusted cut-offs of plasma NfL levels into high and normal NfL (H-NfL and N-NfL, respectively). A multivariable linear regression model was used to assess the value of plasma NfL as predictor of 2-years progression in PD., Results: NfL was higher in PD patients than in controls (p = 0.037). H-NfL (n = 16) group exhibited more severe motor and non-motor symptoms, higher prevalence of malignant phenotype and worse motor progression (MDS-UPDRS-III 11.3 vs 0.7 points, p = 0.003) compared to N-NfL group (n = 76). In linear regression analyses plasma NfL emerged as the best predictor of 2-year motor progression compared to age, sex, disease duration, baseline motor/non-motor variables., Conclusion: increased plasma NfL concentration is associated with malignant PD phenotype and faster motor progression. These findings support the role of NfL assessment as a useful measure for stratifying patients with different baseline slopes of decline in future clinical trials of putative disease-modifying treatments., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
12. Plasma Cystatin C Correlates with Plasma NfL Levels and Predicts Disease Progression in Parkinson's Disease.
- Author
-
Imarisio A, Pilotto A, Garrafa E, Conforti F, Masciocchi S, Turrone R, Gipponi S, Cottini E, Rizzetti MC, Porrini V, Gussago C, Pizzi M, Guadagni F, Zetterberg H, Ashton NJ, Hye A, and Padovani A
- Abstract
Introduction: Previous studies reported increased plasma levels of cystatin C (Cys-C) in Parkinson's disease (PD) and claimed for a possible association with disease severity and progression. The aim of this study was to evaluate plasma Cys-C in PD and healthy controls (HC) and test its association with markers of peripheral inflammation, neurodegeneration, and clinical progression in a longitudinal study., Methods: Plasma Cys-C, high-sensitive C-reactive protein, interleukin 6, and neurofilament light chain (NfL) were assessed at the baseline in 71 consecutive non-demented PD and 69 HC. PD patients underwent an extensive motor and cognitive assessment at baseline and after 2 years of follow-up. The association of Cys-C with disease severity was evaluated in a multilinear model adjusted for the effect of age, sex, disease duration, and peripheral inflammation., Results: Cys-C levels appeared to be higher in PD compared to controls and correlated with the plasma neuronal marker NfL (r = 0.204, p = 0.046). In longitudinal analyses, PD patients with higher Cys-C levels exhibited faster motor progression at 2 years of follow-up independently from the peripheral inflammatory profile., Conclusions: Cys-C was associated with higher NfL levels and a remarkably faster motor progression in PD independently from peripheral inflammation. Further studies are needed in order to understand the mechanisms underpinning the association of Cys-C with higher neuronal damage markers in neurodegenerative diseases., (© 2022 S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF
13. Metal Exposure and SNCA rs356219 Polymorphism Associated With Parkinson Disease and Parkinsonism.
- Author
-
Lucchini RG, Guazzetti S, Renzetti S, Broberg K, Caci M, Covolo L, Crippa P, Gelatti U, Hashim D, Oppini M, Pepe F, Pilotto A, Passeri C, Placidi D, Rizzetti MC, Turla M, Wahlberg K, and Padovani A
- Abstract
Objective: In the province of Brescia, Italy, historical neurotoxic metal exposure has occurred for several decades. This study aimed to explore the role of metal exposure and genetics on Parkinson's Disease (PD) and Parkinsonism. Methods: Cases were enrolled from four local clinics for movement disorders. Randomly selected controls non-affected by neurological or psychiatric conditions were enrolled from the same health centers keeping a similar gender ratio and age distribution as for cases. Data on sociodemographic variables, clinical onset and life habits were collected besides accurate occupational and residential history. Blood samples were collected from all participants for genotyping of target polymorphisms in genes linked to PD and/or metal transport. Results: A total number of 432 cases and 444 controls were enrolled in the study, with average age of 71 years (72.2 for cases and 70 for controls). The average age at diagnosis was 65.9 years (SD 9.9). Among the potential risk factors, family history of PD or Parkinsonism showed the strongest association with the diseases (OR = 4.2, 95% CI 2.3, 7.6 on PD; OR = 4.3, 95% CI 1.9, 9.5 for Parkinsonism), followed by polymorphism rs356219 in the alpha-synuclein ( SNCA ) gene (OR = 2.03, 95% CI 1.3, 3.3 for CC vs. TT on PD; OR = 2.5, 95% CI 1.1, 5.3 for CC vs. TT on Parkinsonism), exposure to metals (OR = 2.4;, 95% CI 1.3, 4.2 on PD), being born in a farm (OR = 1.8; 95% CI 1.1, 2.8 on PD; OR = 2.6; 95% CI 1.4, 4.9 on Parkinsonism) and being born in the province of Brescia (OR = 1.7; 95% CI 1.0, 2.9 on PD). Conditional OR of having PD depending by SNCA polymorphism and metal exposure highlights higher risk of PD among CC SNCA carriers and being exposed to metals. However, the interaction term was not statistically significant. Conclusions: Lifetime exposure to metals and genetic variation in SNCA gene are relevant determinants of PD and Parkinsonism in the highly industrialized area of Brescia, Italy. The lack of evidence of statistical interaction between environmental and genetic factors may be due to the low frequencies of subjects representing the exposure categories and the polymorphism variants and does not rule out the biological interaction., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2020 Lucchini, Guazzetti, Renzetti, Broberg, Caci, Covolo, Crippa, Gelatti, Hashim, Oppini, Pepe, Pilotto, Passeri, Placidi, Rizzetti, Turla, Wahlberg and Padovani.)
- Published
- 2020
- Full Text
- View/download PDF
14. Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment - the ComOn-study.
- Author
-
Geritz J, Maetzold S, Steffen M, Pilotto A, Corrà MF, Moscovich M, Rizzetti MC, Borroni B, Padovani A, Alpes A, Bang C, Barcellos I, Baron R, Bartsch T, Becktepe JS, Berg D, Bergeest LM, Bergmann P, Bouça-Machado R, Drey M, Elshehabi M, Farahmandi S, Ferreira JJ, Franke A, Friederich A, Geisler C, Hüllemann P, Gierthmühlen J, Granert O, Heinzel S, Heller MK, Hobert MA, Hofmann M, Jemlich B, Kerkmann L, Knüpfer S, Krause K, Kress M, Krupp S, Kudelka J, Kuhlenbäumer G, Kurth R, Leypoldt F, Maetzler C, Maia LF, Moewius A, Neumann P, Niemann K, Ortlieb CT, Paschen S, Pham MH, Puehler T, Radloff F, Riedel C, Rogalski M, Sablowsky S, Schanz EM, Schebesta L, Schicketmüller A, Studt S, Thieves M, Tönges L, Ullrich S, Urban PP, Vila-Chã N, Wiegard A, Warmerdam E, Warnecke T, Weiss M, Welzel J, Hansen C, and Maetzler W
- Subjects
- Aged, Brazil, Cognition, Fear, Geriatric Assessment, Germany, Humans, Italy, Portugal, Prospective Studies, Quality of Life, Accidental Falls, Activities of Daily Living
- Abstract
Background: Motor and cognitive deficits and consequently mobility problems are common in geriatric patients. The currently available methods for diagnosis and for the evaluation of treatment in this vulnerable cohort are limited. The aims of the ComOn (COgnitive and Motor interactions in the Older populatioN) study are (i) to define quantitative markers with clinical relevance for motor and cognitive deficits, (ii) to investigate the interaction between both motor and cognitive deficits and (iii) to assess health status as well as treatment outcome of 1000 geriatric inpatients in hospitals of Kiel (Germany), Brescia (Italy), Porto (Portugal), Curitiba (Brazil) and Bochum (Germany)., Methods: This is a prospective, explorative observational multi-center study. In addition to the comprehensive geriatric assessment, quantitative measures of reduced mobility and motor and cognitive deficits are performed before and after a two week's inpatient stay. Components of the assessment are mobile technology-based assessments of gait, balance and transfer performance, neuropsychological tests, frailty, sarcopenia, autonomic dysfunction and sensation, and questionnaires to assess behavioral deficits, activities of daily living, quality of life, fear of falling and dysphagia. Structural MRI and an unsupervised 24/7 home assessment of mobility are performed in a subgroup of participants. The study will also investigate the minimal clinically relevant change of the investigated parameters., Discussion: This study will help form a better understanding of symptoms and their complex interactions and treatment effects in a large geriatric cohort.
- Published
- 2020
- Full Text
- View/download PDF
15. Validation of the Italian version of the PSP Quality of Life questionnaire.
- Author
-
Picillo M, Cuoco S, Amboni M, Bonifacio FP, Bruschi F, Carotenuto I, De Micco R, De Rosa A, Del Prete E, Di Biasio F, Elifani F, Erro R, Fabbri M, Falla M, Franco G, Frosini D, Galantucci S, Lazzeri G, Magistrelli L, Malaguti MC, Milner AV, Minafra B, Olivola E, Pilotto A, Rascunà C, Rizzetti MC, Schirinzi T, Borroni B, Ceravolo R, Di Fonzo A, Marchese R, Mercuri NB, Modugno N, Nicoletti A, Padovani A, Santangelo G, Stefani A, Tessitore A, Volontè MA, Zangaglia R, Zappia M, Zibetti M, and Barone P
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Italy, Male, Psychometrics instrumentation, Reproducibility of Results, Self Report, Psychometrics standards, Quality of Life, Supranuclear Palsy, Progressive diagnosis
- Abstract
Background: Progressive supranuclear palsy (PSP) is a rare rapidly progressive, neurodegenerative disease characterized by falls and ocular movement disturbances. The use of health-related quality of life (HR-QoL) measures allows assessing changes in health status induced by therapeutic interventions or disease progress in neurodegenerative diseases. The PSP-QoL is a 45-item, self-administered questionnaire designed to evaluate HR-QoL in PSP., Methods and Results: Here, the PSP-QoL was translated into Italian and validated in 190 PSP (96 women and 94 men; mean age ± standard deviation, 72 ± 6.5; mean disease duration, 4.2 ± 2.3) patients diagnosed according to the Movement Disorder Society criteria and recruited in 16 third level movement disorders centers participating in the Neurecanet project. The mean PSP-QoL total score was 77.8 ± 37 (physical subscore, 46.5 ± 18.7; mental subscore, 33.6 ± 19.2). The internal consistency was high (Cronbach's alpha = 0.954); corrected item-total correlation was > 0.40 for the majority of items. The significant and moderate correlation of the PSP-QoL with other HR-QoL measures as well as with motor and disability assessments indicated adequate convergent validity of the scale. Gender and geographic location presented a significant impact on the PSP-QoL in our sample with women and patients from the South of Italy scoring higher than their counterparts., Conclusion: In conclusion, the Italian version of the PSP-QoL is an easy, reliable and valid tool for assessment of HR-QoL in PSP.
- Published
- 2019
- Full Text
- View/download PDF
16. Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in α-synucleinopathies.
- Author
-
Pilotto A, Romagnolo A, Tuazon JA, Vizcarra JA, Marsili L, Zibetti M, Rosso M, Rodriguez-Porcel F, Borroni B, Rizzetti MC, Rossi C, Vizcarra-Escobar D, Molano JR, Lopiano L, Ceravolo R, Masellis M, Espay AJ, Padovani A, and Merola A
- Subjects
- Cognitive Dysfunction complications, Cognitive Dysfunction physiopathology, Disease Progression, Humans, Hypotension, Orthostatic physiopathology, Postural Balance, REM Sleep Behavior Disorder physiopathology, Synucleinopathies mortality, Hypotension, Orthostatic complications, REM Sleep Behavior Disorder complications, Synucleinopathies complications, Synucleinopathies physiopathology
- Abstract
Objective: Review the effect of orthostatic hypotension (OH) and rapid-eye-movement sleep behavioural disorder (RBD) on survival, cognitive impairment and postural stability, and discuss pathogenic mechanisms involved in the association of these two common non-motor features with relevant clinical outcomes in α-synucleinopathies., Methods: We searched PubMed (January 2007-February 2019) for human studies of OH and RBD evaluating cognitive impairment, postural instability, and survival in Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA) and pure autonomic failure (PAF). Included studies were analysed for design, key results and limitations as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines., Results: OH and RBD showed a positive association with cognitive impairment in PD and DLB, conflicting association in PAF, and no association in MSA. OH was correlated with incident falls and postural instability in PD and DLB but not in MSA. The association between RBD and postural instability was inconclusive; positive in five studies, negative in seven. OH, but not RBD, correlated with reduced survival in PD, DLB and MSA. The combination of OH and RBD was associated with cognitive impairment and more rapid progression of postural instability., Conclusions: OH and RBD yielded individual and combined negative effects on disability in α-synucleinopathies, reflecting a 'malignant' phenotype of PD with early cognitive impairment and postural instability. Underlying mechanisms may include involvement of selected brainstem cholinergic and noradrenergic nuclei., Competing Interests: Competing interests: AP received speaker honoraria from BioMarin Pharmaceutical, Chiesi Pharmaceuticals, Nutricia Pharmaceuticals, UCB Pharma and Zambon Pharmaceuticals. He received travel grants from AbbVie Pharmaceuticals, BioMarin Pharmaceutical, Nutricia Pharmaceuticals, Zambon Pharmaceuticals and the Italian movement disorder society. AR received speaker honoraria from AbbVie and Chiesi Pharmaceuticals and travel grants from Medtronic, Lusofarmaco and UCB Pharma. JAT has no financial conflicts to disclose. JAV has no financial conflicts to disclose. LM has no financial conflicts to disclose. MZ received speaker honoraria from AbbVie, Medtronic, Zambon and UCB Pharma and received travel grants from AbbVie. MR has no financial conflicts to disclose. FR-P has no financial conflicts to disclose. BB has no financial conflicts to disclose. MCR has no financial conflicts to disclose. CR received speaker honoraria from Zambon and UCB Pharma and received travel grants from Zambon, UCB Pharma, Medtronic and Chiesi Pharmaceuticals. DV-E has no financial conflicts to disclose. JRM has received research support from Axovant. She is also an editorial board member for NEJM Journal Watch Neurology. Leonardo Lopiano received honoraria for lecturing and travel grants from Medtronic, UCB Pharma, and AbbVie. RC received speaker honoraria from General Electric, AbbVie, UCB Pharma, Zambon. He received consulting fees from General Electric and Zambon and grant support from Ministry of Health (MINSAL). MM receives salary support from the Department of Medicine at Sunnybrook Health Sciences Centre and the University of Toronto, as well as the Sunnybrook Research Institute. He has received grants/research Support from: Parkinson Canada, Canadian Institutes of Health Research, Teva, Early Researcher Award - Ministry of Economic Development and Innovation, C5R, Weston Brain Institute, Ontario Brain Institute, Sunnybrook AFP Innovation Fund, Novartis, Washington University, Roche, Alzheimer’s Drug Discovery Foundation (ADDF), Brain Canada, Heart and Stroke Foundation Centre for Stroke Recovery. He has received consulting Fees from UCB, Ionis, Novartis, and Arkuda Therapeutics, as well as royalties from Henry Stewart Talks Ltd. Alberto Espay has received grant support from the NIH, Great Lakes Neurotechnologies and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, Adamas, Acadia, Acorda, Neuroderm, TEVA, Impax, Sunovion, Lundbeck, Osmotica Pharmaceutical and USWorldMeds; publishing royalties from Lippincott Williams and honoraria from Abbvie, UCB, USWorldMeds, Lundbeck, Acadia, Sunovion, the American Academy of Neurology and the Movement Disorders Society. AP received grant support from Ministry of Health (MINSAL) and Ministry of Education, Research and University (MIUR), from CARIPLO Foundation; personal compensation as a consultant/scientific advisory board member for Avanir, Lundbeck, Eli-Lilly, Neuraxpharma, Biogen, GE Health. AM is supported by NIH (KL2 TR001426) and has received speaker honoraria from CSL Behring, Cynapsus Therapeutics, Lundbeck, AbbVie, and Abbott. He has received grant support from Lundbeck and Abbott., (© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
17. Validation of the Italian version of carers' quality-of-life questionnaire for parkinsonism (PQoL Carer) in progressive supranuclear palsy.
- Author
-
Picillo M, Cuoco S, Amboni M, Bonifacio FP, Bruno A, Bruschi F, Cappiello A, De Micco R, De Rosa A, Di Biasio F, Elifani F, Erro R, Fabbri M, Falla M, Franco G, Frosini D, Galantucci S, Lazzeri G, Magistrelli L, Malaguti MC, Milner AV, Minafra B, Olivola E, Pilotto A, Rascunà C, Rizzetti MC, Schirinzi T, Borroni B, Ceravolo R, Di Fonzo A, Lopiano L, Marchese R, Mercuri NB, Modugno N, Nicoletti A, Padovani A, Santangelo G, Stefani A, Tessitore A, Volontè MA, Zangaglia R, Zappia M, and Barone P
- Subjects
- Adult, Aged, Female, Humans, Italy, Male, Middle Aged, Parkinsonian Disorders etiology, Supranuclear Palsy, Progressive complications, Translating, Caregivers psychology, Psychometrics instrumentation, Quality of Life psychology, Surveys and Questionnaires
- Abstract
Progressive supranuclear palsy (PSP) is a rare, rapidly progressive, neurodegenerative disease characterized by falls and ocular movement disturbances. Caring for a partner or relative who suffers from PSP entails a strenuous and demanding task, usually lasting for years that affects carers' everyday life routines and emotional and social well-being. The 26-item Parkinsonism Carers QoL (PQoL Carer) is a self-administered, concise instrument evaluating the quality of life of caregivers of patients with atypical parkinsonism (both PSP and multiple system atrophy). Here, the PQoL Carer was translated into Italian and validated in 162 carers of PSP patients (54.3% women; mean age (standard deviation), 62.4 (15.4)) diagnosed according to the Movement Disorder Society criteria and recruited in 16 third-level movement disorders centers participating in the Neurecanet project. The mean PQoL total score was 40.66 ± 19.46. The internal consistency was excellent (Cronbach's alpha = 0.941); corrected item-total correlation was > 0.40 for all the items. A correlation with other health-related quality of life measures as well as with behavioral assessments was shown suggesting adequate convergent validity of the scale. PQoL also correlated with patients' severity of disease. The discriminant validity of the scale was evidenced by its capacity to differentiate between carers with varying levels of self-reported health (p < 0.001). In conclusion, the Italian version of the PQoL Carer is an easy, consistent, and valid tool for the assessment of the quality of life in carers of PSP patients.
- Published
- 2019
- Full Text
- View/download PDF
18. Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a 123 I-FP-CIT SPECT study.
- Author
-
Pilotto A, Schiano di Cola F, Premi E, Grasso R, Turrone R, Gipponi S, Scalvini A, Cottini E, Paghera B, Garibotto V, Rizzetti MC, Bonanni L, Borroni B, Morbelli S, Nobili F, Guerra UP, Perani D, and Padovani A
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Neural Pathways diagnostic imaging, Radiopharmaceuticals pharmacokinetics, Substantia Nigra diagnostic imaging, Thalamus diagnostic imaging, Tropanes pharmacokinetics, Cerebral Cortex diagnostic imaging, Dopaminergic Neurons metabolism, Lewy Body Disease diagnostic imaging, Parkinson Disease diagnostic imaging, Serotonergic Neurons metabolism, Tomography, Emission-Computed, Single-Photon methods
- Abstract
Purpose: The aim of the study was to evaluate extrastriatal dopaminergic and serotonergic pathways in patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB) using
123 I-FP-CIT SPECT imaging., Methods: The study groups comprised 56 PD patients without dementia, 41 DLB patients and 54 controls. Each patient underwent a standardized neurological examination and123 I-FP-CIT SPECT. Binding in nigrostriatal and extrastriatal regions of interest was calculated in each patient from spatially normalized images. The occipital-adjusted specific to nondisplaceable binding ratio (SBR) in the different regions was compared among the PD patients, DLB patients and controls adjusting for the effects of age, sex, disease duration and serotonergic/dopaminergic treatment. Covariance analysis was used to determine the correlates of local and long-distance regions with extrastriatal123 I-FP-CIT deficits., Results: Both PD and DLB patients showed lower123 I-FP-CIT SPECT SBR in several regions beyond the nigrostriatal system, especially the insula, cingulate and thalamus. DLB patients showed significantly lower123 I-FP-CIT SBR in the thalamus than controls and PD patients. Thalamic and cingulate123 I-FP-CIT SBR deficits were correlated, respectively, with limbic serotonergic and widespread cortical monoaminergic projections only in DLB patients but exhibited only local correlations in PD patients and controls., Conclusion: PD and DLB patients both showed insular dopamine deficits, whereas impairment of thalamic serotonergic pathways was specifically associated with DLB. Longitudinal studies are necessary to determine the clinical value of the assessment of extrastriatal123 I-FP-CIT SPECT.- Published
- 2019
- Full Text
- View/download PDF
19. Subcortical matter in the α-synucleinopathies spectrum: an MRI pilot study.
- Author
-
Gazzina S, Premi E, Turrone R, Acosta-Cabronero J, Rizzetti MC, Cotelli MS, Gasparotti R, Padovani A, and Borroni B
- Subjects
- Analysis of Variance, Chi-Square Distribution, Female, Humans, Image Processing, Computer-Assisted, Italy, Male, Neuropsychological Tests, Pilot Projects, Psychiatric Status Rating Scales, Severity of Illness Index, Brain diagnostic imaging, Dementia diagnostic imaging, Lewy Body Disease diagnostic imaging, Magnetic Resonance Imaging, Parkinson Disease diagnostic imaging, alpha-Synuclein metabolism
- Abstract
α-Synucleinopathies, such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB), are characterized by α-synuclein accumulation from brainstem structures to the neocortex. PD and DLB are clinically distinguishable, while discrimination between Parkinson Disease Dementia (PDD) and DLB can be subtle and based on the temporal relationship between motor and cognitive symptoms. To explore patterns of subcortical atrophy in PD, PDD and DLB, and assess specific differences between PD and PDD, and between DLB and PDD. 16 PD, 11 PDD and 16 DLB patients were recruited and underwent 1.5 Tesla structural MRI scanning. Segmentation of subcortical structures was performed with a well-validated, fully-automated tool, and volume and shape for each structure were compared between groups. PDD and DLB patients showed global subcortical atrophy compared to PD patients. Greater hippocampal atrophy was the specific trait that distinguished PDD from PD, while greater atrophy of the pallidi discriminated DLB from PDD. Vertex analysis revealed specific shape differences in both structures. Our results suggest that automated, time-sparing, subcortical volumetry may provide diagnostically useful information in α-synucleinopathies. Future studies on larger samples and with iron-sensitive MRI contrasts are needed.
- Published
- 2016
- Full Text
- View/download PDF
20. Left parietal cortex transcranial direct current stimulation enhances gesture processing in corticobasal syndrome.
- Author
-
Bianchi M, Cosseddu M, Cotelli M, Manenti R, Brambilla M, Rizzetti MC, Padovani A, and Borroni B
- Subjects
- Aged, Apraxia, Ideomotor etiology, Basal Ganglia Diseases complications, Basal Ganglia Diseases rehabilitation, Female, Humans, Male, Middle Aged, Neurodegenerative Diseases complications, Syndrome, Treatment Outcome, Apraxia, Ideomotor therapy, Arm physiopathology, Gestures, Neurodegenerative Diseases rehabilitation, Parietal Lobe physiopathology, Transcranial Direct Current Stimulation methods
- Abstract
Background and Purpose: Corticobasal syndrome (CBS) is a clinical entity characterized by higher cortical dysfunctions associated with asymmetric onset of levodopa-resistant parkinsonism, dystonia and myoclonus. One of the most typical and distressful features of CBS is limb apraxia, which affects patients in their everyday life. Transcranial direct current stimulation (tDCS) is a non-invasive procedure of cortical stimulation, which represents a promising tool for cognitive enhancement and neurorehabilitation. The present study investigated whether anodal tDCS over the parietal cortex (PARC), would improve ideomotor upper limb apraxia in CBS patients., Methods: Fourteen patients with possible CBS and upper limb apraxia were enrolled. Each patient underwent two sessions of anodal tDCS (left and right PARC) and one session of placebo tDCS. Ideomotor upper limb apraxia was assessed using the De Renzi ideomotor apraxia test that is performed only on imitation., Results: A significant improvement of the De Renzi ideomotor apraxia test scores (post-stimulation versus pre-stimulation) after active anodal stimulation over the left PARC was observed (χ(2) = 17.6, P = 0.0005), whilst no significant effect was noticed after active anodal stimulation over the right PARC (χ(2) = 7.2, P = 0.07). A post hoc analysis revealed a selective improvement in the De Renzi ideomotor apraxia score after active anodal stimulation over the left PARC compared with placebo stimulation considering both right (P = 0.03) and left upper limbs (P = 0.01)., Conclusions: These findings indicate that tDCS to the PARC improves the performance of an ideomotor apraxia test in CBS patients and might represent a promising tool for future rehabilitation approaches., (© 2015 EAN.)
- Published
- 2015
- Full Text
- View/download PDF
21. High doses of cobalt induce optic and auditory neuropathy.
- Author
-
Apostoli P, Catalani S, Zaghini A, Mariotti A, Poliani PL, Vielmi V, Semeraro F, Duse S, Porzionato A, Macchi V, Padovani A, Rizzetti MC, and De Caro R
- Subjects
- Animals, Chlorides pharmacokinetics, Chlorides toxicity, Chromium Compounds pharmacokinetics, Chromium Compounds toxicity, Cobalt pharmacokinetics, Cochlea diagnostic imaging, Cochlea drug effects, Cochlea innervation, Cochlea metabolism, Dose-Response Relationship, Drug, Female, Hair Cells, Auditory drug effects, Hair Cells, Auditory metabolism, Hair Cells, Auditory ultrastructure, Hearing Loss, Central metabolism, Hearing Loss, Central pathology, Heavy Metal Poisoning, Nervous System metabolism, Heavy Metal Poisoning, Nervous System pathology, Male, Microscopy, Electron, Optic Nerve diagnostic imaging, Optic Nerve metabolism, Rabbits, Retina diagnostic imaging, Retina drug effects, Retina metabolism, Retinal Ganglion Cells diagnostic imaging, Retinal Ganglion Cells drug effects, Retinal Ganglion Cells metabolism, Sciatic Nerve diagnostic imaging, Sciatic Nerve drug effects, Sciatic Nerve metabolism, Tissue Distribution, Ultrasonography, Cobalt toxicity, Hearing Loss, Central chemically induced, Heavy Metal Poisoning, Nervous System etiology, Optic Nerve drug effects
- Abstract
The adverse biological effects of continuous exposure to cobalt and chromium have been well defined. In the past, this toxicity was largely an industrial issue concerning workers exposed in occupational setting. Nevertheless, recent reports have described a specific toxicity mediated by the high levels of cobalt and chromium released by metallic prostheses, particularly in patients who had received hip implants. Clinical symptoms, including blindness, deafness and peripheral neuropathy, suggest a specific neurotropism. However, little is known about the neuropathological basis of this process, and experimental evidence is still lacking. We have investigated this issue in an experimental setting using New Zealand White rabbits treated with repeated intravenous injections of cobalt and chromium, alone or in combination. No evident clinical or pathological alterations were associated after chromium administration alone, despite its high levels in blood and tissue while cobalt-chromium and cobalt-treated rabbits showed clinical signs indicative of auditory and optic system toxicity. On histopathological examination, the animals showed severe retinal and cochlear ganglion cell depletion along with optic nerve damage and loss of sensory cochlear hair cells. Interestingly, the severity of the alterations was related to dosages and time of exposure. These data confirmed our previous observation of severe auditory and optic nerve toxicity in patients exposed to an abnormal release of cobalt and chromium from damaged hip prostheses. Moreover, we have identified the major element mediating neurotoxicity to be cobalt, although the molecular mechanisms mediating this toxicity still have to be defined., (Copyright © 2012 Elsevier GmbH. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
22. Analysis of video-polysomnographic sleep findings in dementia with Lewy bodies.
- Author
-
Terzaghi M, Arnaldi D, Rizzetti MC, Minafra B, Cremascoli R, Rustioni V, Zangaglia R, Pasotti C, Sinforiani E, Pacchetti C, and Manni R
- Subjects
- Aged, Arousal, Data Interpretation, Statistical, Depression complications, Depression psychology, Female, Humans, Lewy Body Disease complications, Male, Narcolepsy etiology, Narcolepsy physiopathology, Neuropsychological Tests, Parkinson Disease complications, Parkinson Disease psychology, Psychiatric Status Rating Scales, Sleep Apnea, Central physiopathology, Sleep Wake Disorders etiology, Lewy Body Disease physiopathology, Polysomnography, Sleep physiology, Sleep Wake Disorders physiopathology
- Abstract
Knowledge of sleep architecture and disorders of nocturnal sleep in dementia with Lewy bodies (DLB) is limited by a lack of systematic video-polysomnographic (video-PSG) investigations. We describe video-PSG findings in 29 consecutive subjects diagnosed with DLB. All the patients underwent a clinical interview and overnight video-PSG monitoring. Twenty-nine nondemented patients with Parkinson's disease (PD) matched for age and sex with the DLB cases were selected for comparison. The DLB subjects showed less 1NREM sleep (P = .000) and more 2NREM sleep (P = .000) than the PD subjects. Sleep apnea (30.7% vs. 34.8%) and periodic limb movements (60.9% versus 50.0%) were frequent in both groups. Disruptive motor behavioral manifestations were more frequent in subjects with DLB (69.6% vs. 26.9%, P = .008) and consisted of not only REM sleep behavior disorder (RBD) but also confusional events (30.3% vs. 3.8%, P = .020) and arousal-related episodes mimicking RBD. Subjects with DLB in whom a sleep disturbance had been the presenting symptom performed better than those with other onset symptoms on both the Mini-Mental State Examination (22.2 ± 4.1 vs. 18.1 ± 4.6, P = .019) and the Frontal Assessment Battery (15.8 vs. 10.3, P = .010). Polysomnographic findings in DLB show a complex mix of overlapping sleep alterations: impaired sleep structure, sleep comorbidities, and various motor-behavioral events (not restricted to RBD). Clinicians should be aware of the possibility of misleading symptoms and of the risk of overlooking sleep comorbidities, and consider performing polysomnographic sleep investigations in selected cases. We found evidence that a sleep disturbance as the presenting symptom might indicate a different phenotype of the disease, characterized by milder cognitive impairment., (© 2013 International Parkinson and Movement Disorder Society.)
- Published
- 2013
- Full Text
- View/download PDF
23. Cobalt toxicity after total hip replacement: a neglected adverse effect?
- Author
-
Rizzetti MC, Catalani S, Apostoli P, and Padovani A
- Subjects
- Humans, Peripheral Nervous System Diseases pathology, Arthroplasty, Replacement, Hip adverse effects, Cobalt adverse effects, Hip Prosthesis adverse effects, Peripheral Nervous System Diseases chemically induced, Peripheral Nervous System Diseases physiopathology
- Published
- 2011
- Full Text
- View/download PDF
24. Loss of sight and sound. Could it be the hip?
- Author
-
Rizzetti MC, Liberini P, Zarattini G, Catalani S, Pazzaglia U, Apostoli P, and Padovani A
- Subjects
- Arthroplasty, Replacement, Hip, Chromium blood, Cobalt blood, Diabetes Mellitus, Type 2 complications, Drug Overdose, Female, Humans, Hypertension complications, Middle Aged, Prosthesis Failure, Reoperation, Blindness etiology, Chromium poisoning, Cobalt poisoning, Hearing Loss etiology, Hip Prosthesis adverse effects, Optic Nerve drug effects, Vestibulocochlear Nerve drug effects
- Published
- 2009
- Full Text
- View/download PDF
25. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
- Author
-
Fiorentini C, Rizzetti MC, Busi C, Bontempi S, Collo G, Spano P, and Missale C
- Subjects
- Animals, Cells, Cultured, Corpus Striatum chemistry, Corpus Striatum metabolism, Humans, Male, Oxidopamine, Parkinson Disease, Secondary chemically induced, Protein Subunits analysis, Protein Subunits metabolism, Rats, Rats, Wistar, Receptors, Dopamine D1 analysis, Receptors, Dopamine D1 genetics, Receptors, N-Methyl-D-Aspartate analysis, Synapses chemistry, Transfection, Antiparkinson Agents toxicity, Dyskinesia, Drug-Induced metabolism, Levodopa toxicity, Parkinson Disease, Secondary complications, Receptors, Dopamine D1 metabolism, Receptors, N-Methyl-D-Aspartate metabolism, Synapses metabolism
- Abstract
Glutamate-mediated mechanisms are related to the motor complications of L-DOPA therapy in Parkinson's disease (PD). In striatal postsynaptic densities (PSD), the dopamine D1 receptor (D1R) is part of an oligomeric complex with the glutamate N-methyl-D-aspartate receptor (NMDAR), determining the strength of corticostriatal transmission. We studied D1R/NMDAR complex alterations induced by L-DOPA in the 6-hydroxydopamine-lesioned rat model of PD. L-DOPA-treated hemiparkinsonian rats were determined to be dyskinetic or nondyskinetic based on behavioral testing. D1R/NMDAR assemblies containing NR1-C2 and NR2B subunits were decreased in the PSD of lesioned striatum. Short-term L-DOPA administration improved akinesia and restored the synaptic abundance of D1R, NR1-C2 and NR2B. Prolonged L-DOPA treatment also normalized synaptic D1R/NMDAR complexes in nondyskinetic rats, but remarkably reduced them in the dyskinetic group without changing their interaction. This decrease involved NR1-C2, NR1-C2', NR2A, and NR2B subunits. The composition of residual synaptic D1R/NMDAR complexes in dyskinetic rats may thus be different from that observed in lesioned rats, suggesting that expression of different motor dysfunctions might be related to the receptor profile at corticostriatal synapses. The levels of D1R/NMDAR complexes were unchanged in total striatal membrane proteins, suggesting that the decrease of these species in the PSD is likely to reflect an altered receptor trafficking. In human embryonic kidney 293 cells expressing the D1R/NMDAR, complex costimulation of both D1R and NMDAR, but not individual receptor activation, promoted internalization, suggesting that development of dyskinesias might be related to agonist-mediated down-regulation of the D1R/NMDAR complex at corticostriatal synapses.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.